Xpovio hits endpoints in Phase III multiple myeloma trial
The drug achieved a median progression-free survival of 13.93 months, compared to 9.46 months on Velcade (bortezomib).
Read More
Tag: success
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
